As the weather heats up in the western hemisphere, the temperatures are not the only thing increasing…

In Pharmaland, the oncology space traditionally sees either interesting new data published or a spate of post American Society of Clinical Oncology (ASCO) filings. The summer doldrums often give way to a faster pace in the fall.

Screen Shot 2015-07-06 at 9.50.04 AMOne thing we have been following over the last two years is the T790M race to market in EGFR mutant lung cancer. Clovis Oncology announced last week that they have begun their rolling NDA submission for rociletinib (CO–1686), but what about their keen rival, AstraZeneca with AZD9291?

The company presented new data for AZD9291 jn the EGFR mutant lung cancer upfront setting, but no formal announcement was made about the regulatory status.

There are some potentially interesting new developments to report here, though.

To learn more about what’s happening, subscribers can sign in below or interested folks can sign up in the box.

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTS & WRITERS), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you are in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first. Please note that we do not collect or remit any sales taxes. The purchaser is solely responsible for ensuring compliance with tax laws where they reside or use our content and for the reporting and payment, at their expense, of any use tax or other taxes that may be due as a result of this purchase. An accountant, tax advisor or lawyer should be consulted for advice on any obligation.